Holen Sie sich die Stockscreener-App
27.01
0.55%
-0.15
Handel nachbörslich:
27.01
Schlusskurs vom Vortag:
$27.16
Offen:
$26.91
24-Stunden-Volumen:
1.01M
Relative Volume:
1.22
Marktkapitalisierung:
$1.79B
Einnahmen:
$5.79M
Nettoeinkommen (Verlust:
$-199.61M
KGV:
-8.9734
EPS:
-3.01
Netto-Cashflow:
$-188.48M
1W Leistung:
+2.31%
1M Leistung:
+1.27%
6M Leistung:
+22.16%
1J Leistung:
+4.73%
1-Tages-Spanne:
$26.62
$27.44
1-Wochen-Bereich:
$25.51
$27.65
52-Wochen-Spanne:
$14.40
$30.50
Celldex Therapeutics Inc Stock (CLDX) Company Profile
Firmenname
Celldex Therapeutics Inc
Sektor
Branche
Telefon
908-200-7500
Adresse
53 FRONTAGE ROAD, HAMPTON
Vergleichen Sie CLDX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CLDX
Celldex Therapeutics Inc
|
27.01 | 1.80B | 5.79M | -199.61M | -188.48M | -3.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-21 | Eingeleitet | Mizuho | Outperform |
| 2025-10-13 | Eingeleitet | Barclays | Underweight |
| 2025-04-28 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-03-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-02-13 | Eingeleitet | UBS | Buy |
| 2024-10-07 | Eingeleitet | Citigroup | Buy |
| 2024-09-30 | Eingeleitet | Goldman | Neutral |
| 2024-09-27 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-06-18 | Eingeleitet | Stifel | Buy |
| 2024-06-11 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-20 | Eingeleitet | TD Cowen | Outperform |
| 2023-11-10 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2023-08-22 | Eingeleitet | Wells Fargo | Underweight |
| 2021-09-17 | Eingeleitet | Jefferies | Buy |
| 2021-09-10 | Eingeleitet | SVB Leerink | Outperform |
| 2021-07-22 | Eingeleitet | Guggenheim | Buy |
| 2020-02-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-08-01 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-11-07 | Eingeleitet | Aegis Capital | Buy |
| 2016-03-08 | Herabstufung | Jefferies | Buy → Hold |
| 2016-03-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2016-03-07 | Herabstufung | Leerink Partners | Outperform → Mkt Perform |
| 2016-03-07 | Herabstufung | Wedbush | Outperform → Neutral |
| 2016-03-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-08-11 | Bestätigt | Brean Capital | Buy |
| 2015-08-11 | Bestätigt | Oppenheimer | Outperform |
| 2015-08-11 | Bestätigt | ROTH Capital | Buy |
| 2015-06-02 | Bestätigt | WBB Securities | Strong Buy |
| 2014-11-17 | Bestätigt | ROTH Capital | Buy |
| 2014-03-04 | Bestätigt | Oppenheimer | Outperform |
| 2013-07-08 | Bestätigt | Cantor Fitzgerald | Buy |
| 2013-03-08 | Bestätigt | Cantor Fitzgerald | Buy |
| 2013-02-26 | Bestätigt | Oppenheimer | Outperform |
| 2013-01-10 | Bestätigt | Cantor Fitzgerald | Buy |
| 2012-10-02 | Bestätigt | Oppenheimer | Outperform |
| 2012-09-14 | Bestätigt | Cantor Fitzgerald | Buy |
Alle ansehen
Celldex Therapeutics Inc Aktie (CLDX) Neueste Nachrichten
Celldex Therapeutics (NASDAQ:CLDX) Trading 4.1% HigherShould You Buy? - MarketBeat
Simplify Asset Management Inc. Invests $2.20 Million in Celldex Therapeutics, Inc. $CLDX - MarketBeat
Short Interest in Celldex Therapeutics, Inc. (NASDAQ:CLDX) Declines By 20.9% - MarketBeat
Celldex Therapeutics (NASDAQ:CLDX) Stock Price Crosses Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Barclays Lifts PT on Celldex Therapeutics (CLDX) to $24 From $21 - Insider Monkey
We're Hopeful That Celldex Therapeutics (NASDAQ:CLDX) Will Use Its Cash Wisely - Yahoo Finance
Corient Private Wealth LLC Purchases Shares of 201,717 Celldex Therapeutics, Inc. $CLDX - MarketBeat
12 Small Cap Stocks to Buy with Huge Upside Potential - Insider Monkey
Celldex Therapeutics (CLDX): Assessing Valuation After a Recent Share Price Uptick - Sahm
Income Plays: How sustainable is Celldex Therapeutics Inc. stock dividend payoutGDP Growth & AI Powered Trade Plan Recommendations - Улправда
Will Celldex Therapeutics Inc. stock outperform value stocksJuly 2025 Levels & Weekly High Potential Stock Alerts - DonanımHaber
Will Celldex Therapeutics Inc. stock outperform growth indexesJuly 2025 Spike Watch & Verified Swing Trading Watchlists - DonanımHaber
Will Celldex Therapeutics Inc. stock outperform tech sector in 2025Weekly Trade Summary & Low Volatility Stock Suggestions - Улправда
How Celldex Therapeutics Inc. stock performs after earningsInflation Watch & Stepwise Entry and Exit Trade Signals - Улправда
Aug Summary: Will Celldex Therapeutics Inc. stock see insider buying2025 Momentum Check & Real-Time Buy Signal Alerts - Улправда
Will Celldex Therapeutics Inc. stock see insider buyingInsider Selling & Real-Time Buy Zone Alerts - ulpravda.ru
Barclays Maintains Celldex Therapeutics (CLDX) Underweight Recommendation - Nasdaq
Celldex Therapeutics (NASDAQ:CLDX) Price Target Raised to $24.00 at Barclays - MarketBeat
Argenx, ServiceNow And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
TFG Asset Management GP Ltd Has $6.43 Million Stake in Celldex Therapeutics, Inc. $CLDX - MarketBeat
Bellevue Group AG Has $67.31 Million Stock Holdings in Celldex Therapeutics, Inc. $CLDX - MarketBeat
Eventide Asset Management LLC Lowers Stake in Celldex Therapeutics, Inc. $CLDX - MarketBeat
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Celldex Therapeutics, Inc. $CLDX Shares Sold by Redmile Group LLC - MarketBeat
Should Celldex’s Global Phase 3 EMBARQ Trial for Barzolvolimab in Inducible Urticaria Require Action From CLDX Investors? - Sahm
HighVista Strategies LLC Purchases New Position in Celldex Therapeutics, Inc. $CLDX - MarketBeat
Celldex Therapeutics (NASDAQ:CLDX) Stock Price Down 4.5%Should You Sell? - MarketBeat
Celldex Therapeutics (CLDX) Valuation After Launching Second Global Phase 3 Program for Barzolvolimab - Sahm
Celldex Therapeutics Initiates Global Phase 3 Trial for Barzolvolimab in Cold Urticaria, Symptomatic Dermographism - marketscreener.com
Celldex initiates phase 3 trial for cold urticaria and dermographism drug - Investing.com Canada
Celldex Initiates Global Registrational Phase 3 Program Of Barzolvolimab In Cold Urticaria And Symptomatic Dermographism - TradingView — Track All Markets
Celldex Initiates Global Registrational Phase 3 Program of - GlobeNewswire
19,627 Shares in Celldex Therapeutics, Inc. $CLDX Purchased by Bollard Group LLC - Defense World
Celldex Launches Phase 3 Study for Barzolvolimab in Cold Urticaria and Symptomatic Dermographism - Quiver Quantitative
Celldex Therapeutics SVP & General Counsel Sells Shares - TradingView — Track All Markets
Eczema Clinical Trial Pipeline Accelerates as 100+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - The Manila Times
Eczema Clinical Trial Pipeline Accelerates as 100+ Pharma - GlobeNewswire
Celldex Therapeutics (NASDAQ:CLDX) Reaches New 12-Month HighHere's Why - MarketBeat
Does Celldex Therapeutics Inc (CLDX) offer a good opportunity for investors? - setenews.com
Celldex Therapeutics stock hits 52-week high at $29.14 By Investing.com - Investing.com Nigeria
How Celldex Therapeutics Inc. (TCE2) stock stacks up against competitorsJuly 2025 Levels & Stepwise Entry and Exit Trade Signals - Newser
Can Celldex Therapeutics Inc. (TCE2) stock sustain institutional flowsInflation Watch & Consistent Return Investment Signals - Newser
Celldex Therapeutics stock hits 52-week high at $29.14 - Investing.com India
Fisher Asset Management LLC Sells 49,420 Shares of Celldex Therapeutics, Inc. $CLDX - Defense World
American Century Companies Inc. Grows Position in Celldex Therapeutics, Inc. $CLDX - Defense World
Can Celldex Therapeutics Inc. (TCE2) stock sustain revenue momentumPortfolio Return Summary & Risk Adjusted Buy and Sell Alerts - Newser
Is Celldex Therapeutics Inc. (TCE2) stock testing key supportWeekly Trend Summary & Safe Capital Growth Plans - Newser
Will Celldex Therapeutics Inc. stock outperform international peersWeekly Risk Report & Stepwise Entry/Exit Trade Alerts - Newser
Imvax Gets Positive Overall Survival Data From Phase IIb GBM Asset - Citeline News & Insights
Why Celldex Therapeutics Inc. (TCE2) stock gets analyst attention2025 Key Lessons & Expert Approved Momentum Trade Ideas - Newser
Why Celldex Therapeutics Inc. (TCE2) stock is listed among top recommendationsWeekly Risk Summary & Long-Term Capital Growth Ideas - Newser
Finanzdaten der Celldex Therapeutics Inc-Aktie (CLDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):